Table III.
Evaluation of circulating marker accuracy by ROC curve analysis.
| Overall case series | Breast cancer patients | |||
|---|---|---|---|---|
| Marker | AUC | 95% CI | AUC | 95% CI |
| RANK | 0.58 | 0.35–0.81 | 0.61 | 0.37–0.86 |
| RANKL | 0.74 | 0.54–0.93 | 0.70 | 0.48–0.93 |
| OPG | 0.53 | 0.33–0.72 | 0.52 | 0.32–0.72 |
| RANKL/OPG | 0.60 | 0.41–0.81 | 0.64 | 0.44–0.84 |
| NTX | 0.57 | 0.34–0.79 | 0.60 | 0.38–0.82 |
| CEA | 0.61 | 0.33–0.88 | 0.59 | 0.28–0.91 |
| CA15-3 | 0.73 | 0.48–0.99 | 0.73 | 0.48–0.99 |
AUC, area under the curve; CI, confidence interval; ROC, receiver operating characteristic; RANK, receptor activator of nuclear factor-κB; RANKL, RANK ligand; OPG, osteoprotegerin; NTX, N-terminal telopeptide of type I collagen; CEA, carcinoembryonic antigen; CA, carbohydrate antigen.